Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA withdrawing proposals

This article was originally published in The Tan Sheet

Executive Summary

GMPs for homeopathic products, "Food Labeling, Nutrient Content Claims & Health Claims" among draft proposals FDA is considering withdrawing, according to 1April 22 Federal Register notice. Agency plans to withdraw 84 proposed rules that have not been finalized, are not considered public health priorities, and which have not received agency action in more than 10 years. "FDA's actions are part of an overall regulatory reform strategy initiated by" HHS Secretary Tommy Thompson, the notice states. Commissioner Mark McClellan, MD/PhD, says action is consistent with agency's commitment to "transparency in its regulatory actions." FDA has included a 2press release and 3FAQ page on its Web site to clear up uncertainties; comments will be accepted through July 21...

You may also be interested in...



Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

Topics

UsernamePublicRestriction

Register

PS095392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel